Population Health Sciences

You are here

Home > Publications > Publications

Publications

Found 23 results
Author Title Type [ Year(Asc)]
Filters: Author is Schackman, Bruce R  [Clear All Filters]
2020
Frimpong JA, Shiu-Yee K, Tross S, D'Aunno T, Perlman DC, Strauss SM, Schackman BR, Feaster DJ, Metsch LR.  2020.  Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results: A Randomized Trial.. Med Care.
Jalali A, Ryan DA, McCollister KE, Marsch LA, Schackman BR, Murphy SM.  2020.  Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future.. J Subst Abuse Treat. 112S:18-27.
Nosyk B, Zang X, Krebs E, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Golden M et al..  2020.  Ending the HIV epidemic in the USA: an economic modelling study in six cities.. Lancet HIV.
Behrends CN, Gutkind S, Deming R, Fluegge KR, Bresnahan MP, Schackman BR.  2020.  Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.. J Urban Health.
Wen K, Johnson P, Jeng PJ, Schackman BR, Bao Y.  2020.  State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events.. Med Care.
2019
Schackman BR, Jeng PJ, Flash MJE, Mejia M, Oksuzyan S, Scott JA, Freedberg KA, Kulkarni SP, Garland WH.  2019.  Cost of an HIV Medical Care Coordination Program in Los Angeles County.. J Acquir Immune Defic Syndr. 81(1):e15-e17.
Behrends CN, Eggman AA, Gutkind S, Bresnahan MP, Fluegge K, Laraque F, Litwin AH, Meissner P, Shukla SJ, Perumalswami PV et al..  2019.  A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination.. J Public Health Manag Pract. 25(3):253-261.
Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Yazdi GEftekhari, Stein MD, Freedberg KA, Linas BP.  2019.  Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.. Int J Drug Policy.
Krebs E, Enns B, Wang L, Zang X, Panagiotoglou D, Del Rio C, Dombrowski J, Feaster DJ, Golden M, Granich R et al..  2019.  Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis.. PLoS One. 14(5):e0217559.
Behrends CN, Paone D, Nolan ML, Tuazon E, Murphy SM, Kapadia SN, Jeng PJ, Bayoumi AM, Kunins HV, Schackman BR.  2019.  Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City.. J Subst Abuse Treat. 106:79-88.
Kapadia SN, Johnson P, Schackman BR, Bao Y.  2019.  Hepatitis C Treatment Uptake by New Prescribers After the Introduction of Direct Acting Antivirals.. J Gen Intern Med.
McCrimmon T, Gilbert L, Hunt T, Terlikbayeva A, Wu E, Darisheva M, Primbetova S, Kuskulov A, Davis A, Dasgupta A et al..  2019.  Improving HIV service delivery for people who inject drugs in Kazakhstan: study protocol for the Bridge stepped-wedge trial.. Implement Sci. 14(1):62.
Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP.  2019.  Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.. Drug Alcohol Depend. 200:34-39.
Meinhofer A, Williams ARobin, Johnson P, Schackman BR, Bao Y.  2019.  Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 105:37-43.
Ying R, Fekadu L, Schackman BR, Verguet S.  2019.  Spatial Distribution and Characteristics of HIV Clusters in Ethiopia.. Trop Med Int Health.
Kapadia SN, Johnston CD, Marks KM, Schackman BR, Martin EG.  2019.  Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity.. J Public Health Manag Pract. 25(3):245-252.
Zang X, Krebs E, Wang L, Marshall BDL, Granich R, Schackman BR, Montaner JSG, Nosyk B.  2019.  Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review.. Pharmacoeconomics.
McNeely J, Troxel AB, Kunins HV, Shelley D, Lee JD, Walley A, Weinstein ZM, Billings J, Davis NJ, Marcello RKalyanaram et al..  2019.  Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment.. Addict Sci Clin Pract. 14(1):5.
Nosyk B, Min JEun, Zang X, Feaster DJ, Metsch L, Marshall BDL, Del Rio C, Granich R, Schackman BR, Montaner JSG.  2019.  Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic.. J Int Assoc Provid AIDS Care. 18:2325958218821962.
Murphy SM, Morgan JR, Jeng PJ, Schackman BR.  2019.  Will converting naloxone to over-the-counter status increase pharmacy sales? Health Serv Res. 54(4):764-772.
2018
Murphy SM, McCollister KE, Leff JA, Yang X, Jeng PJ, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR.  2018.  Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.. Ann Intern Med.
2017
Wen H, Schackman BR, Aden B, Bao Y.  2017.  States With Prescription Drug Monitoring Mandates Saw A Reduction In Opioids Prescribed To Medicaid Enrollees.. Health Aff (Millwood). 36(4):733-741.
2016
Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HAlan, Schackman BR.  2016.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.. Health Aff (Millwood). 35(6):1045-51.